A study led by UNC Lineberger researcher Ronald Chen, MD, found that a group of prostate cancer patients reliably reported their own medical histories when their responses were compared to their medical records.
With a $1.74 million grant from the NIH, UNC Lineberger researchers led by H. Shelton Earp, MD, will study a potential new strategy for improving immunotherapy drug responses in patients with melanoma.
UNC-Chapel Hill researchers led by UNC Lineberger member Shawn Hingtgen, PhD, reach a critical milestone for treating brain cancer.
UNC Lineberger researchers find how triple negative breast cancer cells are able to bypass treatment with trametinib, an FDA-approved drug. The researchers also used lab models of breast cancer to test a potential treatment approach that could prevent resistance.
UNC Lineberger researchers Ethan Basch, MD, MSc, and Stephanie Wheeler, PhD, MPH, called for tailored, local-level cancer prevention, screening and treatment efforts to address regional disparities in cancer mortality rates in an editorial published in JAMA on Tuesday.
UNC, NCSU biomedical engineering research team’s findings show that engineered platelets can deliver antibodies to kill cancer cells before they can grow or spread elsewhere in the body.
Unmasking a previously misunderstood gene, University of North Carolina scientists discover an unlikely potential drug target for gastrointestinal cancers.
In a perspective published in the New England Journal of Medicine, Ethan Basch, MD, MSc, professor of medicine and director of UNC Lineberger’s Cancer Outcomes Research Program, addressed the need for – and the barriers preventing – electronic reporting of patients’ symptoms between visits.
UNC scientists led by John Sondek, PhD, created a new biochemical tool to block specific types of downstream G-protein signaling, opening new avenues of research and potential drug design and discovery.
UNC Lineberger researchers reported at the San Antonio Breast Cancer Symposium they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.
Less than 50 percent of surveyed teens found it ‘very believable’ that cigars are not a safe alternative to cigarettes, according to a first-of-its-kind UNC School of Medicine study.
In preliminary findings presented at the 2016 San Antonio Breast Cancer Symposium, researchers showed that older patients were as likely as younger patients to receive targeted therapy and enroll in therapeutic trials based on their sequencing results.
In a study presented at the 2016 San Antonio Breast Cancer Symposium, UNC Lineberger researchers led by Katherine Hoadley, PhD, reported they developed a model that can predict which triple negative breast cancer patients will respond to chemotherapy.
At this year's San Antonio Breast Cancer Symposium, UNC Lineberger researchers and collaborators shared the outcomes of their investigation into the incidence of brain metastasis after a series of drugs were approved to treat HER2-positive metastatic breast cancer, starting with trastuzumab, also known as Herceptin, in the United States in 1998.
As survivability of many cancers increases, so does the opportunity to help survivors live the lives they’d imagined. Manda Miller thought bouts of Hodgkins Lymphoma at 19 and 27 had taken her chance to have children, but Jennifer Mersereau, MD, at UNC Fertility offered an innovative option for the Millers' miracle baby — a donor egg.
UNC Lineberger researchers led by Dr. Timothy R. Gershon report preclinical findings showing promise for targeting a gene linked to microcephaly in infants as a treatment for medulloblastoma.
In the journal Cancer Epidemiology, Biomarkers & Prevention, researchers report that uninsured women under age 65 who received their mammogram at community screening clinics in North Carolina were less likely to get follow-up within a year of a positive mammogram, and had higher odds of missing a 60-day window for follow-up care.
The Oct. 9 episode of CBS News' '60 Minutes' featured UNC Lineberger researchers discussing how they use IBM's Watson to cull through and generate useful clinical insights from massive amounts of genetic data.
Susan G. Komen announced UNC Lineberger researcher Charles M. Perou, PhD, as the recipient of this year's Brinker Award for Scientific Distinction in Basic Science for his contributions to the understanding of breast cancer as distinct molecular subtypes that have prognostic value using cutting-edge cancer genomics tools.
In the study published in the Journal of Clinical Oncology, UNC Lineberger researchers report that nearly a third of a group of patients with chronic myeloid leukemia, and who have federally-funded Medicare health insurance, did not start treatment within six months of diagnosis with any of three targeted drugs that have led to dramatic improvements in survival for the disease.